UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000063701
Receipt number R000072856
Scientific Title Effects of Early Exercise Intervention in Older Patients with Colorectal Cancer Undergoing Oxaliplatin-Based Chemotherapy
Date of disclosure of the study information 2026/11/19
Last modified on 2026/11/19 19:04:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Home-Based Exercise and Chemotherapy adherence in Older Adults with Colorectal Cancer

Acronym

Home-Based Exercise and Chemotherapy adherence in Older Adults with Colorectal Cancer

Scientific Title

Effects of Early Exercise Intervention in Older Patients with Colorectal Cancer Undergoing Oxaliplatin-Based Chemotherapy

Scientific Title:Acronym

Early Exercise in Older Patients with Colorectal Cancer Receiving Oxaliplatin

Region

Japan


Condition

Condition

colorectal cancer

Classification by specialty

Rehabilitation medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse effect of oxaliplatin-a key agent in the pharmacological treatment of colorectal cancer-and may impact the physical function of elderly patients as well as their ability to continue treatment. In this study, we conduct an exploratory analysis of the relationship between exercise intervention and chemotherapy adherence, utilizing data from a prior study that examined the feasibility of a home-based exercise program for elderly colorectal cancer patients undergoing oxaliplatin-based chemotherapy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Oxaliplatin relative dose intensity (RDI) during the first 3 months of treatment and the proportion of patients who maintained an RDI of 85% or higher.

Key secondary outcomes

Cumulative oxaliplatin dose, incidence of CIPN (Grade 2 or higher according to the Common Terminology Criteria for Adverse Events [CTCAE] v4.0), and modifications to the treatment plan due to peripheral neuropathy.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Colorectal cancer patients who initiated oxaliplatin-based outpatient chemotherapy at NHO Tokyo Medical Center between 2019/1/1 and 2024/12/31.

Key exclusion criteria

Patients were excluded if they had difficulty communicating or were unable to understand the study purpose; had a history of prior chemotherapy associated with peripheral neurotoxicity; had neurological disorders (e.g., central nervous system diseases causing motor or sensory impairment) or psychiatric conditions; received only speech-language-hearing therapy; or had any condition deemed inappropriate for participation by the treating physician.

Target sample size

32


Research contact person

Name of lead principal investigator

1st name Motoyasu
Middle name
Last name Takenaka

Organization

NHO Tokyo Medical Center

Division name

Department of Rehabilitation medicine

Zip code

152-8902

Address

2-5-1 Higashigaoka, Meguro-ku, Tokyo

TEL

0334110111

Email

kuma1mie2chibi3@yahoo.co.jp


Public contact

Name of contact person

1st name Chieko
Middle name
Last name Miyata

Organization

NHO Tokyo Medical Center

Division name

Clinial Research Center

Zip code

152-8902

Address

2-5-1 Higashigaoka, Meguro-ku, Tokyo

TEL

0334110111

Homepage URL

https://tokyo-mc.hosp.go.jp/wp-content/uploads/2025/05/R25-001.pdf

Email

kuma1mie2chibi3@yahoo.co.jp


Sponsor or person

Institute

NHO Tokyo Medical Center

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science KAKENHI

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee, National Hospital Organization Tokyo Medical Center

Address

2-5-1 Higashigaoka, Meguro-ku, Tokyo

Tel

03-3411-2526

Email

kuma1mie2chibi3@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

32

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2026 Year 02 Month 17 Day

Date of IRB

2026 Year 03 Month 26 Day

Anticipated trial start date

2026 Year 04 Month 01 Day

Last follow-up date

2026 Year 08 Month 30 Day

Date of closure to data entry

2026 Year 08 Month 30 Day

Date trial data considered complete

2026 Year 08 Month 30 Day

Date analysis concluded

2026 Year 09 Month 30 Day


Other

Other related information

This retrospective, comparative, secondary analysis included older patients with colorectal cancer receiving oxaliplatin-based chemotherapy who had participated in a 12-week home-based exercise program in a prospective feasibility study, as well as a historical usual-care control group.


Management information

Registered date

2026 Year 11 Month 19 Day

Last modified on

2026 Year 11 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072856